丙型肝炎病毒感染供者向未感染受者提供肾移植:KDIGO 2022丙型肝炎临床实践指南更新的系统评价
为更新2018 KDIGO丙型肝炎指南,本系统评价纳入16项研究共557例HCV D+/R-肾移植并接受DAA治疗者,SVR12达97.7%,DAA严重不良事件罕见(0.4%),移植后≥1年受者死亡2.1%、移植物存活97.6%,证据确定性普遍较低。
要点
- HCV D+/R-肾移植后DAA治疗SVR12为97.7%(95%CI 96.3%-98.8%)。
- DAA治疗严重不良事件罕见,发生率为0.4%(95%CI 0.1%-2.8%)。
- 移植后≥1年受者死亡2.1%(95%CI 0.9-3.7),移植物存活97.6%(95%CI 95.7%-98.9%)。
核心结论
- HCV感染供者向未感染受者肾移植后接受DAA治疗似乎安全,并与良好的1年临床结局相关。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Cochrane、CINAHL和ClinicalTrials.gov至2022年2月1日,以及2019至2021年会议和2018 KDIGO HCV指南,纳入单组(D+/R-)或比较D+/R-与D-/R-肾移植的研究,数据提取在SRDR-Plus中由第二位研究者复核,采用最大似然Meta分析,证据确定性按GRADE评估。
主要发现
- 共纳入16项研究(N=557)。
- 治疗结束后12周持续病毒学应答(SVR12)为97.7%(95%CI 96.3%-98.8%)。
- 超短疗程治疗(≤8天)导致部分患者出现病毒血症而需标准疗程DAA治疗,所有患者经1个或罕见2个DAA疗程后均达到SVR12。
- D+/R-移植后DAA治疗的严重不良事件罕见,发生率为0.4%(95%CI 0.1%-2.8%)。
- D+/R-移植后≥1年,受者死亡发生率为2.1%(95%CI 0.9-3.7),移植物存活率为97.6%(95%CI 95.7%-98.9%)。
关键数值与推荐
- SVR12为97.7%(95%CI 96.3%-98.8%)。
- DAA治疗严重不良事件发生率为0.4%(95%CI 0.1%-2.8%)。
- 移植后≥1年受者死亡发生率为2.1%(95%CI 0.9-3.7)。
- 移植后≥1年移植物存活率为97.6%(95%CI 95.7%-98.9%)。
- 移植后1年估算肾小球滤过率范围为46至74mL/min/1.73m2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 分析普遍基于低确定性证据。
- D+/R-移植的长期安全性和有效性存在不确定性。
- 研究超短疗程治疗的研究较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) has made transplantation of kidneys from HCV-infected donors to uninfected recipients (D+/R-) feasible. To facilitate an update to the 2018 KDIGO guideline for patients with CKD and HCV, we conducted a systematic review of HCV D+/R-kidney transplantation coupled with DAA treatment. STUDY DESIGN: Systematic review and meta-analysis. SETTING & STUDY POPULATIONS: We included studies of HCV D+/R-kidney transplantations that used any DAA protocol. SELECTION CRITERIA FOR STUDIES: Based on a search of PubMed, Embase, Cochrane, CINAHL, and ClinicalTrials.gov through February 1, 2022, conferences from 2019 to 2021, and the 2018 KDIGO HCV guideline we identified single-group (D+/R-) or comparative studies of D+/R-versus D-/R-kidney transplantation. DATA EXTRACTION: Conducted in SRDR-Plus with review by a second researcher. ANALYTICAL APPROACH: Maximum likelihood meta-analyses; the certainty of evidence was assessed per GRADE (Grading of Recommendations Assessment, Development and Evaluation). RESULTS: We identified 16 studies (N=557). A sustained viral response at 12 weeks after treatment (SVR12) was observed in 97.7% (95% CI, 96.3%-98.8%). Ultrashort duration treatment (≤8 days) resulted in viremia requiring standard-course DAA treatment in some patients, all of whom achieved SVR12 after 1 or rarely 2 DAA courses. Serious adverse events from DAA treatment were rare after D+/R-transplantation (0.4% [95% CI, 0.1%-2.8%]). At≥1 year after D+/R-transplantation, recipient death occurred in 2.1% (95% CI, 0.9-3.7) and allograft survival was 97.6% (95% CI, 95.7%-98.9%). Estimated glomerular filtration rate 1 year after transplantation ranged from 46 to 74mL/min/1.73m2. LIMITATIONS: Analyses were generally based on low-certainty evidence. Uncertainty exists about the long-term safety and efficacy of D+/R-transplantation. Few studies investigated ultrashort treatment courses. CONCLUSIONS: Kidney transplantation from HCV-infected donors to uninfected recipients followed by DAA treatment appears to be safe and associated with excellent 1-year clinical outcomes. PLAIN-LANGUAGE SUMMARY: Due to the high efficacy of direct-acting antivirals (DAA), the use of kidneys from HCV-infected deceased donors may increase rates of kidney transplantation. We conducted a systematic review for the 2022 KDIGO Clinical Practice Guideline on Hepatitis C to evaluate the safety and efficacy of kidney transplantation from HCV-infected donors to uninfected recipients (D+/R-) followed by DAA therapy. Sixteen studies comprising 557 patients revealed high rates of sustained viral response, low rates of adverse events, and excellent patient and allograft survival 1 year after transplantation. Kidney transplantation from HCV-infected deceased donors to uninfected recipients treated with DAA appears safe and effective. Future studies should investigate shorter treatment durations, monitor safety, and obtain longer-term efficacy data.
引用
- Gordon CE, Adam GP, Jadoul M, et al. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update. Am J Kidney Dis. 2023. PMID: 37061019. doi:10.1053/j.ajkd.2022.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。